Blog Profile / Focus on Funds


URL :http://blogs.barrons.com/focusonfunds
Filed Under:Business & Finance / Investing
Posts on Regator:11477
Posts / Week:32.5
Archived Since:February 17, 2011

Blog Post Archive

Bitcoin to $11,000? Heck. Let’s Make It $11,500!

Fundstrat's Thomas Lee raised his mid-2018 target for Bitcoin to $11,500 from $6,000 established mid-August. He sees Bitcoin Investment Trust going to $1,300.

Those Darn Oil Stocks! Stuck Between Survive and Thrive

Royal Dutch Shell and Southwestern Energy down, after analyst downgrades. North American E&P companies are sitting somewhere "between survive and thrive" says AllianceBernstein.

When Quiet Really Is Too Quiet: Dow Gains 70 Points On Muted Thanksgiving Week Monday

Stocks ticked higher today, as the market continued its low-volatility ways. Is it trying to tell us something?

This Party’s Not Over: Why It Pays to Stick With Big Tech

Strong fundamentals and less risk means tech and internet retailers are still a buy.

Don’t You Wish We All Could Have Our Very Own Activist Investor?

Shares of Bloomin' Brands have jumped more than 10% after Jana reported a stake in the company.

Give Thanks For This Bounty? Industrials Get One More Chance With Deere

Deere will be one of the last industrial stocks to report this quarter. Will its earnings give the industrial sector-and the ETF that tracks it--a boost?

Biotech: What You Don’t Know…And What You Don’t Know You Don’t Know…Could Hurt You

One biotech analyst lays bare the challenges in predicting how science success will translate into profits.

Think You Know What Drives Bank Stocks Higher? Think Again

Bank have been trading on macro factors and the yield curve, but there's still a strong relationship between earnings estimate revisions and stock performance.

Boil That Frog! Are U.S. Investors in Hot Water?

One investment banks warns that tough times could be ahead for U.S. equity investors but don't see the real trouble starting until 2019.

Easy Come, Easy Go: Biotech’s Fading Flows

Biotech funds slow after two consecutive weeks of net inflows. The iShares Nasdaq Biotechnology ETF and the SPDR S&P Biotech ETF are showing some weakness Friday morning.

Take That: Trian Triumphs Over P&G

P&G's stock is rising after a proxy vote recount showed that Nelson Peltz won a seat on the company's board by a narrow margin.

Anti-Genocide Activist Sees Hope in Vanguard Vote

About 20% of shareholders rejected Vanguard's recommendation and supported genocide-free investing.

Watcha Doin’ Harvard? Why a Bet Against the VIX Is Just Plain Weird

The CBOE Volatility Index spiked to 14.5 early Tuesday morning and is hanging out at the 13 level as of this afternoon. Meanwhile in ETF land, the leveraged ProShares Ultra VIX Short-Term Futures (ticker: UVXY) is up more than 5% and its unleveraged sister ProShares VIX Short-Term Futures (VIXY) notched a 2.5% gain. Harvard Management […]

General Electric: A Value Investor’s Worst Nightmare?

GE has been a money loser for investors looking to buy cheap, beaten-up stocks. But it's not the only stock that has made life painful for value investors this year.

Does This Retail Rally Ring True?

The SPDR S&P Retail ETF is up 0.65% so far Tuesday. But if history is any guide, this rally could get "snuffed out" like the rest, says one technical analyst.

Berkshire Still Likes Financials, Adds to Apple

Berkshire Hathaway added to positions in banks and other U.S. financials in the third quarter, and shifted some technology holdings.

Icahn Capital Trims Major AIG Position

Filings from Carl Icahn's Icahn Capital showed the fund sold some of its AIG and Freeport McMoRan stake.

Copyright © 2015 Regator, LLC